JINKO is NOVA’s unified in silico clinical trial simulation platform.


With Artificial Intelligence and virtual populations at the heart of NOVA’s innovative approach, the platform takes its name from the fortunate homonymic collision of the Japanese words for ‘artificial’ (人工, jinkō) and ‘population’ (人口, jinkō).

Learn more

We help biotech and pharma companies generate new insights, de-risk and accelerate research programs and reduce cost of development.

We build mathematical models of disease and treatment based on knowledge extracted from literature and real-world patient data.

  • Discovery

    Streamline target identification & secure early proof of concept

    Learn more
  • Clinical development

    Optimize trial design and capture best responders

    Learn more
  • Market access

    Demonstrate value to payers

    Learn more

content Do you want to learn more about in silico clinical trials ?

Take a look at our white book

Go to download page
In Silico white book

We are NOVA

We pride ourselves on attracting the most talented individuals in our industry. Our interdisciplinary team combines expertise in biology, medicine, clinical pharmacology, applied mathematics, data science, artificial intelligence and software development.

We are a trusted partner

  • Enyo
  • Takeda
  • Janssen
  • Innate
  • omPharma
  • Theratech
  • op2
  • Erytech
  • Elsalys
  • Shire

Check out our latest updates

  • In silico

    From Clinical Trial Efficacy to Real‑Life Effectiveness: Why Conventional Metrics do not Work

    Why is there a need to develop and validate functional and relevant translation approaches for the translation of clinical trial efficacy to the real-world setting.

    Read more
  • Financials

    NOVA raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform

    The funds will be used to advance NOVA’s in silico clinical trial simulation platform, JINKO; to faciliate the Company’s expansion into the US; and develop a COVID-19 disease model in collaboration with Sanofi.

    Read more
  • Partnership

    ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease

    NOVA awarded €2.4 million to leverage Jinkō®, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease

    Read more


Is here to answer your questions or requests.

Do you have any questions for me?

If you want to join the team, please visit our careers section to see all vacancies available

Select a team please
First name is required
Last name is required
Job title is required
Company is required
Email is not valid
Message is required